Bevacizumab Plus Irinotecan Plus Carboplatin for Recurrent Malignant Glioma (MG)

Phase 2 Completed 104 enrolled Annick Desjardins

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether Bevacizumab, CPT-11 and Carboplatin in combination are effective in the treatment of recurrent malignant glioma.

Timeline

Start: 2009-09
Primary completion: 2012-07
Completion: 2013-01

Publications

Reardon DA, Desjardins A, Peters KB, Gururangan S, Sampson JH, McLendon RE, Herndon JE 2nd, Bulusu A, Threatt S, Friedman AH, Vredenburgh JJ, Friedman HS. Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naive, recurrent glioblastoma. J Neurooncol. 2012 Mar;107(1):155-64. doi: 10.1007/s11060-011-0722-2. Epub 2011 Oct 11.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bevacizumab	Monoclonal antibody	10 mg/kg	—
Subject	Carboplatin	Small molecule	4 unknown	—
Subject	Irinotecan	Small molecule	125 mg/m2	—
Subject	Irinotecan	Small molecule	340 mg/m2	—

Bevacizumab Plus Irinotecan Plus Carboplatin for Recurrent Malignant Glioma (MG)

Summary

Timeline

Publications

Drugs

Indications